drugset
drugset / Trial / NCT06968585

A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy

NCT06968585 ↗

Phase 3 Active not recruiting 365 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

Evaluation of the efficacy of A166 versus trastuzumab emtansine (T-DM1) in Patients with HER2-Positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane therapy

Timeline

Start
2023-07-18
Primary completion
2026-11-30
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TRASTUZUMAB BOTIDOTIN Unknown 4.8 mg/kg Intravenous
Comparator Trastuzumab emtansine Other / unclassified 3.6 mg/kg Intravenous

Indications

HER2 positive breast carcinoma